Company Overview
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue +18.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 18.80% |
Stock Price Performance
| 1 Year: | -32.63% |
| 6 Months: | -55.65% |
| 3 Months: | +13.54% |
| 1 Month: | -4.10% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.44 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 62.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OCS Oculis Holding AG PHARMA | 12.16 | -7.24 | $675.22M | 0.00% | -41.00% | -43.70% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 19.97M | 20.77M | 20.30M | 20.63M | 21.73M |
| Operating Income | - | -19.97M | -20.77M | -20.30M | -20.63M | -21.73M |
| EBITDA | - | -32.84M | -25.10M | -16.53M | -23.30M | -28.62M |
| Interest Expense | - | 247.00K | 183.00K | 162.00K | 241.00K | 173.00K |
| Pretax Income | - | -33.21M | -25.40M | -16.84M | -23.70M | -28.95M |
| Tax Provision | - | 7.00K | -24.00K | 13.00K | -182.00K | -98.00K |
| Net Income | - | -33.21M | -25.38M | -16.86M | -23.51M | -28.85M |
| Diluted EPS | - | -0.69 | -0.49 | -0.32 | -0.42 | -0.49 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 32.38M | 45.85M | 73.20M | 81.67M |
| Operating Income | -32.38M | -45.85M | -73.20M | -81.67M |
| EBITDA | -31.90M | -87.09M | -84.89M | -97.76M |
| Interest Expense | 6.44M | 1.31M | 639.00K | 833.00K |
| Pretax Income | -38.64M | -88.69M | -85.94M | -99.14M |
| Tax Provision | 55.00K | 107.00K | -160.00K | -186.00K |
| Net Income | -38.70M | -88.80M | -85.78M | -98.96M |
| Diluted EPS | -11.32 | -2.97 | -2.12 | -1.89 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 37.06M | 114.35M | 120.35M | 235.96M |
| Current Assets | - | 23.66M | 101.02M | 104.90M | 218.89M |
| Cash & Equivalents | - | 19.79M | 38.33M | 27.71M | 81.33M |
| Inventory | - | - | - | - | - |
| Receivables | - | 1.08M | 1.20M | 1.51M | 1.79M |
| Total Liabilities | - | 135.05M | 20.62M | 46.97M | 39.89M |
| Current Liabilities | - | 12.02M | 19.09M | 44.23M | 36.75M |
| Long Term Debt | 113.50M | 122.45M | - | - | - |
| Total Debt | - | 633.00K | 605.00K | 1.18M | 2.31M |
| Total Equity | - | -97.99M | 93.73M | 73.38M | 196.07M |
| Shares Outstanding | - | 32.73M | 36.65M | 44.66M | 58.69M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -25.07M | -55.04M | -48.92M | -66.30M |
| Investing Cash Flow | - | -3.55M | -52.97M | -16.08M | -60.93M |
| Financing Cash Flow | - | 1.71M | 129.63M | 53.98M | 186.92M |
| Capital Expenditure | - | -3.55M | -48.00K | -230.00K | -1.39M |
| Free Cash Flow | - | -28.62M | -55.09M | -49.15M | -67.69M |
| Net Change in Cash | - | -26.91M | 21.62M | -11.03M | 59.68M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 39.5% | -94.7% | -116.9% | -50.5% |
| ROCE % | -129.3% | -48.1% | -96.2% | -41.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Eqt Fund Management S.a R.l. | 11.99% | 6.95M | $70.48M |
| 2 | Gildi - Lifeyrissjodur | 4.19% | 2.43M | $24.64M |
| 3 | Aberdeen Group plc | 3.72% | 2.16M | $21.90M |
| 4 | Millennium Management Llc | 3.52% | 2.04M | $20.71M |
| 5 | Pivotal bioVenture Partners Investment Advisor, LLC | 2.60% | 1.51M | $15.27M |
| 6 | Citadel Advisors Llc | 1.70% | 987.20K | $10.01M |
| 7 | Braidwell LP | 1.44% | 834.18K | $8.46M |
| 8 | Perceptive Advisors Llc | 1.39% | 808.83K | $8.20M |
| 9 | Saturn V Capital Management LP | 1.18% | 684.88K | $6.94M |
| 10 | SR One Capital Management, LP | 1.11% | 641.02K | $6.50M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OCS
Precision Trading with Oculis Holding Ag (OCS) Risk Zones - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxObkh6aTdFN05nWU44dkg2UzJfeVZ4VDdudEJnMWRtT1dlSFdmY0xyTUZKcjlYa2UwT0sxVWVxTVVsMXhCZUxLNi1sN21feEZuanZWZWlhVWF6b2MzekMyY2tnRUdsYWdJRWdjaFViZmtNMHptTlVpblNfQm5fdkRwbDNKSHdPSW1nd3BtSD…
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPN01XWXlPRWNNdlBrZzZJZnVlcWdKWmdla202c29sUW9kdHBxb1RtbEoydkNQR0tZRXdsdlI1dHptakVTZUtEN1ZZbGFUV0wyS0hKRWk1WUJlUkpuX1had20wOWptazJNTUdoSldtdEotRmxWWXRSMkFCRGNXLUd2d1ZvX0RqeVlwSUFpWG…
Berenberg downgrades Mitie Group stock rating on OCS bid price - Investing.com
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOSUV0ZVkxMEZXX2VVWVlNdXBqemMyUmJUV2NNTWpZem5RU3pHaWluM3NvMHN1RDJCY2JMVTByYVlpMjRhX1RqLWY0MlA5T3dXSHVkYV84eDBPTVIya2FyRl9uQ0MxM1ljMHI2UWFpWm82SnI5aG9FQ2gxTGR6S0ZNU3gxNnhncXgzYURsQ3…
Four Oculis directors' restricted stock units vest in Aug. 13 notifications - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQNEJ6cVoyMnp0LUcwNWRYN3Y2ZURVbDBxdUUwaDNpeDZTM2lOYnZzekxaVlpVMTdHQVBXbnVVWEJsZ2RJcEpxam5vTXZKU2htT1pMQ0JlMVV2bGgtUkFIdTJMUmg2Vzc3ZVdyRFJwS3dlMTBpSHh6WjVFQ1BqZTI3c1RDM2NKQjZmS3ZBN1…
Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNTXJpR0VsYWhJUVN2SnNJbldjQXd1TVN3LTJyYU9BM1lyVWVkaWZpLWFhSTZMLURjQWZqNHBVSi03c2JIMkhhakwxQU5FN1lsV1JJekdXNldPTHY3NDVRMlN5SFNsR1ZsMGcxTFNXM0ZkeUtoOUY3VDB1anlXZ3R6MDlreE9XUGxtT0tsVW…
Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS) - PR Newswire
<a href="https://news.google.com/rss/articles/CBMiigJBVV95cUxQYURKUUR4X3B2bDdMeGdUM2RHRXk2YjVHTmcxTDBXT1A0TGlUUGFLckNhR29XbUVlajFjN3oyMThiZzBBcWlZMmJuZllCeXlSNWp5WlotV1FpYlg1ZDJyclBIZXJDU0NXVVZZMEtzMmZNTUtNbGhsUm93SUl6NXkwWjFpcjVRMHhsV3N5cz…
OCS — Frequently Asked Questions
What is the current share price of Oculis Holding AG (OCS)?
As of 2026-09-19 21:16 PDT, Oculis Holding AG (OCS) trades at $12.16 on NasdaqGM. Its 52-week range is $10.71 to $32.65.
What is the market capitalisation of OCS?
Oculis Holding AG (OCS) has a market capitalisation of $675.22M on NasdaqGM.
What is the P/E ratio of OCS?
OCS trades at a trailing price-to-earnings (P/E) ratio of -7.24. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.34.
What is the return on equity (ROE) of OCS?
OCS has a return on equity (ROE) of -43.70%. Its return on capital employed (ROCE) is -41.00%.
Is OCS a good stock to buy?
This page provides a data-driven analysis of Oculis Holding AG (OCS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.